Zacks Investment Research on MSN1d
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...
Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
Regeneron price target lowered to $1,000 from $1,100 at JPMorgan
JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...
Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows
We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...
Taiwan News5d
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Paris and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic ...